Syndax Pharmaceuticals Inc Stock Price, News & Analysis

Syndax (Nasdaq: SNDX) reported $45.9M total revenue for 3Q25, including $32.0M Revuforj net revenue and $13.9M collaboration revenue from Niktimvo. Revuforj prescriptions rose ~25% QoQ (~850 scripts) and Revuforj received FDA approval on Oct 24, 2025 and NCCN category 2A listing for R/R NPM1m AML. Incyte reported $45.8M Niktimvo net sales; Syndax recorded 50% product contribution. Cash, cash equivalents and investments were $456.1M, which the company expects will fund it to profitability. Reported 3Q25 net loss was $60.7M. Conference call held Nov 3, 2025.

Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event with a live webcast on Monday, December 8, 2025 at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting.

Company management and multiple key opinion leaders will discuss data updates from the Revuforj (revumenib) and Niktimvo (axatilimab-csfr) programs. A live webcast and a replay will be available on the Investor section of the company website at www.syndax.com for a limited time.

Syndax (Nasdaq: SNDX) announced that 23 abstracts, including 6 oral presentations, featuring Revuforj (revumenib) and Niktimvo (axatilimab) data were accepted for presentation at the ASH Annual Meeting, Dec 6-9, 2025 in Orlando.

Revumenib abstracts cover frontline and relapsed/refractory acute leukemia, combination regimens (venetoclax + decitabine/cedazuridine; intensive chemo; gilteritinib), real-world experience, and post-HSCT maintenance. Axatilimab abstracts address dosing feasibility, long-term therapy in R/R chronic GVHD, combination with ruxolitinib in newly diagnosed chronic GVHD, biomarker/pharmacodynamic analyses, and a Phase 3 trial in initial therapy.

The company will host an in-person investor event with a live webcast on Dec 8, 2025 at 7:00 a.m. ET.

Syndax (Nasdaq: SNDX) announced management will participate in multiple investor conferences in November 2025, featuring fireside chats by CEO Michael A. Metzger and other executives.

Scheduled appearances: UBS Global Healthcare Conference on Nov 10, 2025 at 11:00 a.m. ET; Guggenheim Healthcare Innovation on Nov 11, 2025 at 3:00 p.m. ET; Stifel Healthcare Conference on Nov 13, 2025 at 10:00 a.m. ET; and Jefferies London Healthcare Conference on Nov 20, 2025 at 10:00 a.m. GMT / 5:00 a.m. ET.

A live webcast and limited-time replay will be available in the Investor section at www.syndax.com.

Syndax (Nasdaq: SNDX) will report third quarter 2025 financial results and provide a business update on Monday, November 3, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day.

Investors can access the live webcast and slides via the Investors & Events page on the company website or join by phone using Conference ID: Syndax3Q25 (Domestic: 800-590-8290; International: 240-690-8800). A replay will be available on the Investors site about 24 hours after the call and remain accessible for 90 days.

Syndax (NASDAQ: SNDX) announced FDA approval of Revuforj (revumenib) on October 24, 2025 for treatment of relapsed or refractory (R/R) acute myeloid leukemia with a susceptible NPM1 mutation in adults and pediatric patients one year and older with no satisfactory alternative options.

The approval expands Revuforj’s prior 2024 indication for R/R acute leukemia with a KMT2A translocation, making it the first FDA-approved menin inhibitor for multiple acute leukemia subtypes. Approval was supported by AUGMENT-101 Phase 2 data showing CR+CRh 23% (15/65), median time to response 2.8 months, and median duration of response 4.5 months. Revuforj is included in the NCCN Guidelines as a category 2A option for R/R NPM1m AML and KMT2A-rearranged acute leukemia.

Syndax Pharmaceuticals (Nasdaq: SNDX) announced on October 1, 2025 that it granted inducement awards under its 2023 Inducement Plan to 10 new employees to purchase up to 138,900 shares of common stock. The awards are stock options that vest over four years: 25% vest on the one‑year anniversary of the vesting commencement date and the remaining shares vest monthly at 1/48th per month over the following 36 months, subject to continued service. The grants were reported under Nasdaq Listing Rule 5635(c)(4).

Syndax Pharmaceuticals (NASDAQ:SNDX) announced that its drug Revuforj® (revumenib) has been included in the NCCN Guidelines® as a category 2A treatment recommendation for relapsed or refractory NPM1 mutated acute myeloid leukemia (AML). The update follows positive results from the AUGMENT-101 trial published in Blood in 2025.

The drug maintains its category 2A recommendation for R/R acute leukemia with KMT2A rearrangement. Syndax has submitted a supplemental New Drug Application (sNDA) for revumenib with Priority Review status and a PDUFA date of October 25, 2025.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement stock options to 11 new employees. The awards, issued under the Company's 2023 Inducement Plan, allow for the purchase of up to 167,400 shares of common stock.

The stock options feature a four-year vesting schedule, with 25% of shares vesting after one year and the remaining vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment.